D. Boral Capital Reaffirms Buy Rating for FibroBiologics (NASDAQ:FBLG)

FibroBiologics (NASDAQ:FBLG)‘s stock had its “buy” rating reaffirmed by D. Boral Capital in a report released on Tuesday,Benzinga reports. They presently have a $16.00 target price on the stock.

Several other equities research analysts have also recently issued reports on FBLG. Rodman & Renshaw began coverage on shares of FibroBiologics in a report on Thursday, December 12th. They issued a “buy” rating and a $12.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of FibroBiologics in a research note on Tuesday. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $13.00.

FibroBiologics Stock Up 8.9 %

FibroBiologics stock opened at $0.94 on Tuesday. FibroBiologics has a one year low of $0.86 and a one year high of $13.59. The business’s fifty day moving average is $1.26 and its 200 day moving average is $2.13.

FibroBiologics (NASDAQ:FBLG) last announced its quarterly earnings results on Monday, March 31st. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. As a group, research analysts anticipate that FibroBiologics will post -0.53 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in FBLG. Geode Capital Management LLC grew its position in shares of FibroBiologics by 90.0% during the 3rd quarter. Geode Capital Management LLC now owns 599,760 shares of the company’s stock valued at $1,854,000 after acquiring an additional 284,047 shares during the period. Barclays PLC lifted its position in FibroBiologics by 363.2% during the third quarter. Barclays PLC now owns 39,958 shares of the company’s stock valued at $123,000 after purchasing an additional 31,331 shares in the last quarter. Virtu Financial LLC bought a new stake in FibroBiologics during the fourth quarter valued at about $30,000. Jane Street Group LLC purchased a new stake in FibroBiologics in the third quarter worth about $37,000. Finally, State Street Corp raised its stake in shares of FibroBiologics by 26.5% in the third quarter. State Street Corp now owns 475,837 shares of the company’s stock worth $1,470,000 after buying an additional 99,789 shares during the period.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.